Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Measuring MRD: methods and challenges

Jill Corre, PharmD, PhD, of L’Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France, gives an overview on the tools available for the assessment of measure measurable residual disease (MRD) in patients with multiple myeloma, such as next generation sequencing (NGS) and flow cytometry. Dr Corre explains the difference between the methods, reporting that it is often difficult to directly compare results obtained from different methods. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.